OBX (34) IVA (49) JBIO (31) ANRO (35) ⌘ Pro Terminal →

Alumis Inc. (ALMS) — RQD Stock Rating Cockpit

$6.73 -2.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.69

Alumis Inc. (ALMS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $891.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALMS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Alumis Inc. (NASDAQ: ALMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $6.73 (-2.32% 1D, market cap $891.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALMS compare to OBX and IVA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALMS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OBX (Obsidian Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, ALMS leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALMS?

▼

Per ALMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847367), Alumis Inc. generated $24.1M in revenue, -$243.3M in net income, and -$370.2M in free cash flow against $411.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.69 (-0.61%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALMS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY ALMS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (37% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.06-10.2% Next Q

Q2 (-2Q)

Grade E$6.34+2.7% Next Q

Q3 (-1Q)

Grade E$6.51+3.4% Next Q

Current

Grade E$6.73-12% Hist 90D α

Trajectory: E (27) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALMS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALMS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.51) and Max Pain ($7.07) forces dealer call-delta covering toward $32.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

39.930 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE9% OF RANGE

L: $4$6.73H: $31

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 0 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ALMS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (23)

7/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like ALMS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALMS)

✓Walkthrough of ALMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.35%🛡️ HOLDING TREND SUPPORT

2026-11-02O $7.13H $7.13L $6.73C $6.73VOL 2.74M

RES: $40.82SUP: $4.82SMA50: $9.51SMA200: $21.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALMS Butterfly Map → + Track ALMS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALMS)

Health Care Rank #998 of 1016 ⚔️ OBX vs ALMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALMS vs. OBX, IVA, JBIO, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alumis Inc. (ALMS) ranks #998 by composite RQD confidence (19/100, grade E) and #378 by equity capitalization ($891.8M). Within this direct 5-issuer industry benchmark cohort, ALMS leads on earnings valuation at N/A trailing P/E, while ALMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ALMS at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALMS ACTIVE Alumis Inc.	E	19/100	—	—	-35.0%	-2.32%	$891.8M	Benchmark Subject
OBX Obsidian Therapeutics Inc.	E	34/100	—	—	-35.0%	+1.86%	$896.9M	/obx-vs-alms →
IVA Inventiva S.A. American Depository Shares	D	49/100	—	—	—	-2.14%	$881.3M	/iva-vs-alms →
JBIO Jade Biosciences Inc.	E	31/100	—	—	-35.0%	-1.26%	$905.6M	/jbio-vs-alms →
ANRO Alto Neuroscience Inc.	D-	35/100	—	—	-35.0%	-3.71%	$921.0M	/anro-vs-alms →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847367

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alumis Inc. (ALMS) reported GAAP revenue of $24.1M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$243.3M, operating cash flow of -$369.5M, and free cash flow of -$370.2M (-44.1% YoY). On the balance sheet, ALMS closed FY2025 with $411.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$24.1M	-$243.3M	-$369.5M	-$370.2M	$411.9M	—
FY2024 (FY)	2024-12-31	$0	-$294.2M	-$255.1M	-$256.8M	$341.0M	—
FY2023 (FY)	2023-12-31	$0	-$155.0M	-$130.0M	-$130.0M	—	—

3. ALMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALMS compare to OBX and IVA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALMS?

Where is ALMS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALMS last traded at $6.73 (-2.32% on volume of 2,236,914 shares), positioning the stock -29.23% below its 50-day simple moving average ($9.51) and -68.45% below its 200-day simple moving average ($21.33). Across its 52-week range of $4.39 to $31.35, ALMS sits at the 8.7% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.89 to $7.57).

ALMS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALMS stock right now?

Alumis Inc. (ALMS) currently earns a Roarable Rating of E (Strong Sell — SELL) with 19/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ALMS's 12-month price target and RQD AI Jury consensus?

ALMS's 12-month base price target is $5.55 (range $4.33 to $32.92), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALMS RQD Cockpit ALMS 12M Forecast ALMS Earnings & Move ALMS Dividends & DRIP ALMS Insiders & 13F ALMS Whale Options ALMS Profit Sankey ALMS News & Why

ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALMS — Alumis Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALMS carries an RQD Score of 19 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 0 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For an investor, this means the business is not currently generating returns on capital or free cash, so any valuation rests on future expectations rather than present cash output.
Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is low, indicating limited supportive institutional flow in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-conviction signals in the source data.
Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity read. The stock is assessed as moderately exposed to broad market movement without a strong macro-fit advantage.
Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings point to elevated financial distress risk and weak balance-sheet quality.

Taken together, the rating frames ALMS as a high-risk name where the primary upside case depends on events outside current cash generation, while the forensic and cash-flow pillars flag significant downside risk. The prospective investor should weigh the valuation tradeoff: a market cap of $891.8M against negative ROIC and zero FCF yield means the price embeds expectations the reported financials do not yet support.

Business

Alumis Inc. (ALMS) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is categorized at a market capitalization of $0.9B. The source data does not specify its products, customers, or revenue model beyond the sector and industry classification. Per the SEC financials, FY 2025 revenue was $24.1M while FY 2024 revenue was $0.0M.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$24.1M	$-453.8M	$-243.3M	N/A	$-370.2M	$89.7M	N/A
FY 2024	$0.0M	$-300.8M	$-294.2M	N/A	$-256.8M	$169.5M	N/A
FY 2023	$0.0M	$-158.2M	$-155.0M	N/A	$-130.0M	N/A	N/A

Per the SEC financials, operating margin and net margin are each -60%, and gross margin is 0%. Per the Roarable RQD rating, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash declined from $169.5M in FY 2024 to $89.7M in FY 2025 while free cash flow remained deeply negative, indicating ongoing cash consumption.

Recent Catalysts & News Wire Analysis

Positive Phase 3 data (Quiver Quantitative, GREEN/YELLOW): The headline reports positive Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis and advancement toward a 2026 NDA filing. This is the most substantive catalyst cited.
Analyst reiteration on TYK2 data (Investing.com, YELLOW): H.C. Wainwright reiterated its rating on TYK2 data.
Valuation risk flag (Investing.com, RED / RISK WATCH): An InvestingPro Fair Value headline flagged ALMS as overvalued before a 46% fall.
Competitor-read headline (Yahoo Finance, GREEN / CATALYST): An article on Almirall's lebrikizumab data is related by theme but is not a direct ALMS event.
Market-signal and conference items (YELLOW): A real-time signals article and an unrelated Alvotech investor-conference notice appear in the feed.
Proprietary liquidity signal (Butterfly Supply-Chain Graph, BULLISH, severity 94): The signal reports a 3.63x True Net Liquidity elasticity and a Macro Tailwind Score of 96/100, with the Net Liquidity Index at $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps). The regression correlation is r = -0.17, a weak statistical relationship that should temper reliance on the elasticity figure.
Price action: Per the market data, the price is $6.89, down -3.37%, on volume of 2743493.

Open Questions

What are ALMS's specific products, revenue sources, and customers, given that FY 2025 revenue of $24.1M is reported without a source description?
What is the current cash runway, given cash of $89.7M against FY 2025 free cash flow of $-370.2M?
What is the debt structure, since debt is N/A across all reported periods despite a stated Debt/Equity of 0.5?
What are the timing and regulatory status of the envudeucitinib NDA filing referenced in the catalyst headline?
What is the consensus analyst view and price target, which are absent from the source data?

ALMS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alumis Inc. (ALMS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALMS Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 5h ago

H.C. Wainwright reiterates Alumis stock rating on TYK2 data

Investing.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 8h ago

Is Almirall (BME:ALM) A Bargain As Lebrikizumab Data Strengthens Its Valuation Case?

Yahoo Finance report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com • 11h ago

InvestingPro Fair Value flagged Alumis as overvalued before 46% fall By Investing.com

Investing.com report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 14h ago

Alumis Reports Positive Phase 3 ONWARD Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis, Advances Toward 2026 NDA Filing | ALMS Stock News

Quiver Quantitative report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 17h ago

Avoiding Lag: Real-Time Signals in (ALMS) Movement

Stock Traders Daily report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 20h ago

Alvotech to present at multiple investor conferences in November 2026

Pluang report covering Alumis Inc. (ALMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALMS Bull vs. Bear Conversation Board — What's Your Call at $6.73?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALMS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.06 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALMS (E • RQD 19/100) a Buy at $6.89?

Welcome to the ALMS (Alumis Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.79 (-16.0%)

Spot @ $6.89

Pump the brakes on ALMS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALMS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Alumis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.20 (+19.0%)

Spot @ $6.89

ALMS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALMS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.89 (52-wk range $4.39 - $31.35), any beat on forward guidance forces shorts and underweight funds to chase.